Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated December 13, 2022, reports on Cellectis S.A.'s presentation of preliminary clinical data at the 64th Annual Meeting of the American Society of Hematology (ASH). The filing focuses on two Phase 1/2a trials: BALLI-01 (evaluating UCART22 for relapsed/refractory acute lymphoblastic leukemia) and AMELI-01 (evaluating UCART123 for relapsed/refractory acute myeloid leukemia).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a clinical update and does not contain financial statements.
Material Changes and Clinical Updates
- UCART22 (BALLI-01 Trial): Data from five additional patients at dose level 3 (DL3) with FCA lymphodepletion showed no dose-limiting toxicities (DLTs) or Grade 2+ cytokine release syndrome (CRS). Anti-tumor activity was observed in 60% (3/5) of patients, including one durable MRD-negative complete response (CRi) lasting over 6 months.
- UCART123 (AMELI-01 Trial): Adding alemtuzumab to the lymphodepletion regimen (FCA) resulted in significantly higher cell expansion compared to FC alone. However, the FCA arm experienced two Grade 5 DLTs (deaths) secondary to CRS. Despite this, two patients at DL2 with FCA achieved meaningful responses, including one durable MRD-negative CR lasting over one year.
- Protocol Modifications: Following a pause due to a Grade 5 event, the AMELI-01 protocol was amended to include a second dose of UCART123 after 10-14 days and the use of prophylactic tocilizumab to mitigate CRS risk.
- Pipeline Updates: Servier notified Allogene of discontinuing involvement in CD-19-targeting allogeneic CAR T-cell products. Cellectis is enrolling patients in NATHALI-01 (UCART20x22 for NHL) and MELANI-01 (UCARTCS1 for multiple myeloma).
Outlook, Risks, and Management Commentary
Management views the preliminary data as supportive of continuing UCART22 and UCART123 administration with FCA lymphodepletion. The company expects the next data set for BALLI-01 in 2023. The filing includes extensive forward-looking statements cautioning that preliminary results from small patient cohorts are not predictive of future outcomes. Key risks include the potential for subsequent data to contradict early results, manufacturing delays, regulatory inquiries, and the inherent risks of biopharmaceutical development.
Investor Verification Checklist
- Verify the safety profile of the FCA lymphodepletion regimen given the Grade 5 events in the AMELI-01 trial.
- Confirm the timeline and enrollment status for the modified AMELI-01 2-dose regimen arm.
- Monitor the impact of Servier's discontinuation of CD-19-targeting products on Cellectis's licensing revenue and pipeline strategy.
- Review upcoming 2023 data releases for UCART22 to confirm durability of responses.
- Assess the company's cash runway and capital requirements, as this filing does not disclose current liquidity.